• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value

Logo: Sanofi Canada (CNW Group/Sanofi Canada)

News provided by

Sanofi Canada

Dec 12, 2017, 13:12 ET

Share this article

Share this article


  • Results of studies comparing Sanofi's Toujeo® and insulin degludec
  • Clinical implications for people living with diabetes

LAVAL, QC, Dec. 12, 2017 /CNW Telbec/ - Sanofi Canada announces the results of recent studies comparing Sanofi's Toujeo® (insulin glargine 300 Units/mL or Gla-300) to insulin degludec 100 Units/mL (Deg-100). The results show positive data that could lead to a better understanding of optimal treatment for more than 3.4 million Canadians living with diabetes.1 Each of these co-related studies concludes that Toujeo® is a longer-acting insulin, provides a constant glucose lowering effect over 24 hours with a once-daily administration, low within day variability and clinical benefits.2

The pharmacokinetic/pharmacodynamic (PK/PD) study comparing Sanofi's Toujeo® and insulin degludec

The full results of this first PK/PD study with Toujeo® and Deg-100 were presented on November 11, 2016, during the 16th Annual Diabetes Technology Meeting in Bethesda, Maryland, U.S.3 The results showed that the Toujeo® PK/PD profile was flatter at a clinically relevant dose (0.4 U/kg/day, the average dose used in worldwide clinical practice)4 and more evenly distributed over 24 hours than the profile of insulin degludec for patients with type 1 diabetes. The within-day fluctuation of metabolic activity was 20% lower (p=0.047) for Toujeo® than insulin degludec. An overall flat PK/PD profile and an evenly distributed exposure over 24 hours were observed for Toujeo® at both dose levels studied (0.4 and 0.6 U/kg/day).

"This is not the first time Toujeo® is compared to other insulins, and consistently showed positive results," said Dr. Hisham A.S. Mahmoud, Medical Director at Sanofi Canada. "Toujeo® has already demonstrated an improved PK/PD profile when compared to insulin glargine 100 Units/mL (Gla-100). In a previous CGM study (continuous glucose monitoring) comparing Gla-300 and Gla-100, Toujeo® showed lower between-day variability and lower within-day fluctuations, associated with a lower risk of nocturnal confirmed (≤3 mmol/L) or severe hypoglycemia."5

The results observed in the PK/PD study confirm that Toujeo® has the potential to help people with diabetes reach their targets with lower risk of hypoglycemia. Furthermore, these results became the platform for the following ground studies.

The LIGHTNING and Deliver D studies

The findings of two comparative real-world studies, LIGHTNING and Deliver D, show that adults with diabetes who switched their basal insulin therapy to Toujeo® or insulin degludec experienced similar numbers of low blood sugar (hypoglycemia) events. Patients also experienced similar reductions of average blood sugar level (HbA1c) with both insulin treatments. These results were presented on November 30 at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, California, U.S.6,7

"The LIGHTNING and Deliver D studies extend Sanofi's program of retrospective observational analyses comparing Toujeo® with other basal insulins in a real-world setting and reinforce the consistency of evidence gathered across several patient populations," said Dr. Mahmoud. "In this case, throughout these two studies, we compared Toujeo® and insulin degludec based on two different large U.S. databases of electronic medical records and claims using a statistical technique in order to make the treatment groups comparable. This approach minimizes observed sources of bias typically found in simple observational studies."

The results of this comparison between Toujeo® and insulin degludec from the LIGHTNING and Deliver D studies could be reinforced, and thus, confirmed, with the results of the clinical trial called BRIGHT, intended to be released in 2018.   

The BRIGHT study

The BRIGHT study is the first head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo® and insulin degludec 100 Units/mL.8

"We are proud to say that Sanofi's Toujeo® met the primary study objective, which was to determine if the effect of Toujeo® on blood sugar levels (HbA1c) was similar to insulin degludec," mentioned Dr. Riccardo Perfetti, Head of Global Diabetes Medical Team, ‎Sanofi.

Secondary objectives included the percentage of patients experiencing adverse events, the total number of participants with low blood sugar events during the study and the rate at which low blood sugar events occurred. The study specifically followed 929 adults whose type 2 diabetes was previously uncontrolled on non-insulin medication.

"Reducing the incidence of hypoglycemic events without compromising blood sugar reduction is an ongoing challenge for HCPs when managing their patients, commented Dr. Alice Y.Y. Cheng, Endocrinologist at Credit Valley Hospital and St. Michael's Hospital and Associate Professor, Department of Medicine, University of Toronto. "The most recently introduced long-acting insulins have demonstrated benefits to adult patients with diabetes. From the perspective of physicians and patients, hypoglycemia remains a major limiting factor in effective blood sugar management in diabetes."

The release of this new data contributes to the body of evidence for positive patient outcomes with Toujeo® in people with diabetes. The findings of the BRIGHT study are consistent with previous pharmacological studies, including the EDITION Phase 3 clinical trial program.9,10,11,12

"All these results demonstrate how Toujeo® can bring value to people living with diabetes," claimed Niven Al-Khoury, President at Sanofi Canada. "With over 100 years of experience of working to understand and support the healthcare needs of Canadians, being able to bring solutions is core to our purpose."

Diabetes in Canada

Diabetes affects approximately 3.4 million Canadians, of which type 2 diabetes accounts for 90% of cases.13,14 It is estimated that 5.7 million Canadians have prediabetes; this condition being characterized by blood glucose levels above normal, but not high enough to be diagnosed as diabetes. Fifty percent of individuals with prediabetes will develop type 2 diabetes.15 Left untreated, diabetes can lead to many serious complications, such as heart disease, kidney disease, loss of vision and amputation of the lower limbs.

About Toujeo®
Toujeo® is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Toujeo® has been approved by the U.S. Food and Drug Administration (FDA), the European Commission, Health Canada, the Therapeutic Goods Administration in Australia, and the MHLW in Japan (where its approved brand name is Lantus® XR), and is under review by other regulatory authorities around the world.

About Sanofi Diabetes and Cardiovascular
Diabetes and cardiovascular disease affect millions of people worldwide, with many managing the complex challenges of both. Building on its portfolio evolution, heritage and expertise, Sanofi has implemented a focused business unit dedicated to delivering innovative, value-based medicines and integrated solutions in these therapeutic areas. It is committed to a collaborative approach that involves strategic alliances with professional and patient associations, research institutions and leaders in healthcare and other industries, with the goal of advancing scientific knowledge, driving the convergence of science and technology, helping to improve outcomes and inspiring an evolution in care.

About Sanofi www.sanofi.ca
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur, and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Together, Sanofi entities in Canada employ close to 1,900 people. In 2016, Sanofi companies invested $130 million in research and development in Canada, creating jobs, economic activity and opportunities throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.



1http://www.diabetes.ca/how-you-can-help/advocate/why-federal-leadership-is-essential/diabetes-statistics-in-canada.
2Becker RH, Nowotny I, Teichert L, et al. "Low within- and between-day variability in exposure to new insulin glargine 300 U/ml". Diabetes Obes Metab. 2015; 17(3): 261-7.
3Bailey T, et al. "Insulin Glargine 300 U/mL (Gla-300) Provides More Stable and More Evenly Distributed Steady-state PK/PD Profiles Compared with Insulin Degludec in Type 1 Diabetes". Poster presented at Diabetes Technology Meeting, November 11, 2016.  
4Data on file, Adelphi Real World Diabetes DSP XII, 2015.
5Bergenstal RM, et al. Diabetes Technol Ther 2015; 17(S1): 16 (Abstract 39).
6Zhou LF et al, "Hypoglycemia risk associated with basal insulin use in type 2 diabetes (T2DM): The Lightning study", World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, CA, U.S., November 30 – December 2, 2017.
7Blonde L et al, "Real-world evidence demonstrates comparable clinical outcomes of switching from insulin glargine 100 U/mL (Gla-100) to insulin glargine 300 U/mL (Gla-300) vs insulin degludec (IDeg) in patients with type 2 diabetes (T2D)", World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, CA, U.S., November 30 – December 2, 2017.
8Sanofi, data on file: "Insulin glargine 300 U/mL vs insulin degludec in insulin-naïve adults with T2DM: head-to-head trial design and rationale", NCT02738151, November 2017.
9Riddle MC et al. Diabetes Care. 2014; 37(10): 2755-62, DOI: 10.2337/dc14-0991.
10Yki-Järvinen H, et al. Diabetes Care. 2014; 37(12): 3235-43, DOI: 10.2337/dc14-0990.
11Bolli GB, et al. Diabetes Obes Metab. 2015; 17(4): 386–94, DOI: 10.1111/dom.12438.
12Ritzel R, et al. Diabetes Obes Metab. 2015; 17(9): 859-67, DOI: 10.1111/dom.12485.
13Diabetes Canada, "Diabetes statistics in Canada": http://www.diabetes.ca/how-you-can-help/advocate/why-federal-leadership-is-essential/diabetes-statistics-in-canada.
14Diabetes Québec, "Type 2 diabetes": http://www.diabete.qc.ca/en/understand-diabetes/all-about-diabetes/types-of-diabetes/type-2-diabetes.
15Diabetes Canada, "Prediabetes": https://www.diabetes.ca/about-diabetes/prediabetes.

SOURCE Sanofi Canada

For further information: Sanofi Canada, Catherine R. Cunningham, Tel.: 514-713-1634, [email protected]; Massy Forget Langlois Public Relations, Bridget Ann Peterson, Tel.: 514-842-2455, ext. 26, [email protected]

Related Links

http://www.sanofi.ca

Modal title

Organization Profile

Sanofi Canada

    Also from this source

  • Health Canada accepts nirsevimab regulatory submission for infant RSV

Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET

  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2023 CNW Group Ltd. All Rights Reserved. A Cision company.